To test the efficacy of therapeutically targeting UCP2 in established lung fibrosis, we initiated treatment of injured aged mice on day 22 after bleomycin administration (1.5 U/kg) with oropharyngeal UCP2 (or non‐targeting, NT) siRNA (Figure 6b). Here, UCP2 is linked to pulmonary fibrosis.